23andMe Investor Presentation Deck

Strategic Investments in Future Growth Potential FY2022 Guidance* (updated 2/10/22) Revenue $268 to $278 million Adjusted EBITDA -$148 to -$163 million Net Loss -$205 to -$220 million *Financial year ends March 31, 2022

View entire presentation